SLC5A2 and type 2 diabetes mellitus: Taken together, the completed preclinical studies to date suggest that SGLT2 inhibitors positively influence multiple factors strongly associated with improvements in diastolic function in T2DM, and possibly through a combination of indirect on-target and direct off-target effects.